Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DOMHNASDAQ:ITRMNASDAQ:NRBONASDAQ:NRSN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDOMHDominari$5.43-4.4%$5.01$0.83▼$13.58$83.25M0.57298,620 shs303,377 shsITRMIterum Therapeutics$0.94-4.6%$1.03$0.81▼$3.02$39.60M2.781.05 million shs560,999 shsNRBONeuroBo Pharmaceuticals$0.68-3.4%$0.75$2.08▼$5.30$5.83M-0.2651,808 shs51,705 shsNRSNNeuroSense Therapeutics$2.13-9.4%$1.50$0.51▼$2.60$32.12M1.61276,431 shs512,971 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDOMHDominari-4.40%+8.17%+18.04%+0.18%+185.79%ITRMIterum Therapeutics-4.59%-5.54%+1.37%-33.01%-23.82%NRBONeuroBo Pharmaceuticals0.00%-7.65%-14.40%-57.21%-83.35%NRSNNeuroSense Therapeutics-9.36%-13.06%+40.13%+93.64%+137.19%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDOMHDominari1.0125 of 5 stars0.03.00.00.01.92.50.6ITRMIterum Therapeutics1.876 of 5 stars3.55.00.00.00.60.00.0NRBONeuroBo PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ANRSNNeuroSense Therapeutics1.6145 of 5 stars3.53.00.00.00.01.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDOMHDominari 0.00N/AN/AN/AITRMIterum Therapeutics 3.00Buy$9.00852.78% UpsideNRBONeuroBo Pharmaceuticals 0.00N/AN/AN/ANRSNNeuroSense Therapeutics 3.00Buy$14.00557.28% UpsideCurrent Analyst Ratings BreakdownLatest NRBO, ITRM, DOMH, and NRSN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2025NRSNNeuroSense TherapeuticsD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/12/2025NRSNNeuroSense TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.005/8/2025ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$9.00(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDOMHDominari$18.15M4.38N/AN/A$5.71 per share0.95ITRMIterum TherapeuticsN/AN/AN/AN/A($0.15) per shareN/ANRBONeuroBo PharmaceuticalsN/AN/AN/AN/A$1.50 per shareN/ANRSNNeuroSense TherapeuticsN/AN/AN/AN/A$0.19 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDOMHDominari-$14.70M-$4.50N/A∞N/A-167.73%-91.67%-77.80%8/6/2025 (Estimated)ITRMIterum Therapeutics-$24.77M-$0.99N/A∞N/AN/AN/A-71.37%8/13/2025 (Estimated)NRBONeuroBo Pharmaceuticals-$12.47MN/A0.00N/AN/AN/A-189.12%-122.31%8/12/2025 (Estimated)NRSNNeuroSense Therapeutics-$10.21M-$0.54N/A∞N/AN/AN/A-445.40%6/24/2025 (Estimated)Latest NRBO, ITRM, DOMH, and NRSN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/24/2025Q1 2025NRSNNeuroSense Therapeutics-$0.13N/AN/AN/AN/AN/A5/13/2025Q1 2025ITRMIterum Therapeutics-$0.14-$0.14N/A-$0.14N/AN/A4/15/2025Q4 2024DOMHDominariN/A$0.20N/A$0.20N/A$6.56 million4/7/2025Q4 2024NRSNNeuroSense Therapeutics-$0.12-$0.06+$0.06-$0.06N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDOMHDominariN/AN/AN/AN/AN/AITRMIterum TherapeuticsN/AN/AN/AN/AN/ANRBONeuroBo PharmaceuticalsN/AN/AN/AN/AN/ANRSNNeuroSense TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDOMHDominariN/A5.745.74ITRMIterum TherapeuticsN/A3.723.58NRBONeuroBo PharmaceuticalsN/A2.412.41NRSNNeuroSense TherapeuticsN/A2.212.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDOMHDominari42.48%ITRMIterum Therapeutics9.21%NRBONeuroBo Pharmaceuticals1.37%NRSNNeuroSense Therapeutics1.04%Insider OwnershipCompanyInsider OwnershipDOMHDominari32.98%ITRMIterum Therapeutics9.20%NRBONeuroBo Pharmaceuticals1.05%NRSNNeuroSense Therapeutics27.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDOMHDominari414.64 million9.81 millionNot OptionableITRMIterum Therapeutics1040.00 million36.32 millionNot OptionableNRBONeuroBo Pharmaceuticals108.62 million8.53 millionNot OptionableNRSNNeuroSense Therapeutics1013.67 million9.92 millionNot OptionableNRBO, ITRM, DOMH, and NRSN HeadlinesRecent News About These CompaniesNeuroSense Therapeutics (NRSN) Expected to Announce Earnings on TuesdayJune 17, 2025 | americanbankingnews.comTop Nasdaq Companies by Market Cap Ranked by KalkineJune 7, 2025 | kalkinemedia.comNeurosense, awaiting Canada approval, scales PrimeC productionMay 15, 2025 | alsnewstoday.comD. Boral Capital Initiates Coverage of NeuroSense Therapeutics (NRSN) with Buy RecommendationMay 14, 2025 | msn.comWhy This Nano-Cap Stock Might Skyrocket To $14, Per Analyst InsightsMay 12, 2025 | benzinga.comNeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market LaunchMay 7, 2025 | prnewswire.comNeuroSense Therapeutics Advances ALS Treatment and Strategic PartnershipApril 24, 2025 | tipranks.comNeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership UpdateApril 24, 2025 | prnewswire.comNeuroSense Therapeutics Presents Promising Phase 2b Data on PrimeC for ALS at AAN MeetingApril 10, 2025 | sohu.comNeuroSense Therapeutics Reports Year-End 2024 Financial Results and Provides Business UpdatesApril 10, 2025 | sohu.comNeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS TreatmentApril 9, 2025 | prnewswire.comNeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business UpdatesApril 7, 2025 | prnewswire.comNeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology MeetingApril 4, 2025 | prnewswire.comMarket Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS DrugMarch 20, 2025 | businesswire.comNeuroSense Advances PrimeC Commercialization in CanadaMarch 19, 2025 | tipranks.comPESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment LandscapeMarch 17, 2025 | businesswire.comLife Saving Innovation in Neurodegenerative Disease Treatment: An Interview with Alon Ben-Noon, CEO & Founder of NeuroSense TherapeuticsMarch 12, 2025 | techbullion.comNeuroSense Therapeutics Reports Positive Phase 2b Study Results for ALS TreatmentFebruary 19, 2025 | tipranks.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Elevance Health (ELV) and Genmab (GMAB)February 4, 2025 | markets.businessinsider.comNeuroSense regains Nasdaq complianceJanuary 8, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNRBO, ITRM, DOMH, and NRSN Company DescriptionsDominari NASDAQ:DOMH$5.43 -0.25 (-4.40%) As of 06/23/2025 04:00 PM EasternDominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.Iterum Therapeutics NASDAQ:ITRM$0.94 -0.05 (-4.59%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$0.95 +0.01 (+0.78%) As of 07:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.NeuroBo Pharmaceuticals NASDAQ:NRBO$0.68 -0.02 (-3.41%) As of 06/20/2025NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene. NeuroBo Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.NeuroSense Therapeutics NASDAQ:NRSN$2.13 -0.22 (-9.36%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$2.21 +0.08 (+3.71%) As of 06:46 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
